Brino 500 Mg 20 Capsules
Brand : sami pharm (pvt) ltd.
How it works
Tranexamic acid competitively inhibits activation of plasminogen(via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
BRINO CAP 500 MG 20'S
Requires Prescription (YES/NO)
Tranexamic acid is indicated for the treatment of: - Hemorrhage or risk of hemorrhage in increased fibrinolysis or fibrinogenolysis .
Hypotension has occurred, particularly after rapid intravenous dosage. Thrombotic complications have been reported in patients receiving tranexamic acid, but these are usually a consequence of its inappropriate use. There have been a few instances of transient disturbance of color vision associated with use of tranexamic acid. Hypersensitivity skin reactions have also been reported.
When not to Use
Tranexamic acid is contraindicated in patients with:- Known hypersensitivity to tranexamic acid or to any of the excipient of the product.- Acute thromboembolic disease such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis.- Fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding.
Adults : ORAL: Loral fibrinolysis : 15-25mg/kg body weight two-three times daily. Menorrhagia : Initiated when heavy bleeding started , 1-1.5gm 3-4 times daily for 3-4 days . Hereditary angioedema : 1-1.5gm 2-3 times daily . Epistaxis : 1 gm three times daily for 7 days. Always consult your doctor or pharmacist for dose adjustment.
Storage yes or /no
Store this medicine at room temperature, away from direct light and heat.
Before use of tranexamic acid, risk factors of thromboembolic disease should be considered. In patients with a history of thromboembolic diseases or in those with increased incidence of thromboembolic events in their family history (patients with a high risk of thrombophilia), tranexamic acid should only be administered if there is a strong medical indication and under strict medical supervision.
Tranexamic acid should be administered with care in patients receiving oral contraceptives because of the increased risk of thrombosis.
Patients with irregular menstrual bleeding should not use tranexamic acid until the cause of the irregularity has been established.
Convulsions have been reported in association of tranexamic acid treatment.
Always consult your physician before using any medicine.
Estrogens , Thrombolytic drugs.
syr bd 1cc insulin 6mm syringe 1s
disprin 300mg dispersible tablets 100s (pack size 10 x 10s)
panadol 500mg tablets 200s ( pack size 20x10s)